Journal: Frontiers in Chemistry

Article Title: Rational Design of Antiangiogenic Helical Oligopeptides Targeting the Vascular Endothelial Growth Factor Receptors

doi: 10.3389/fchem.2019.00170

Figure Lengend Snippet: Antiangiogenic activity of analogues 5 and 6 . The images are representative phase contrast photomicrographs of HUVECs plated on Matrigel under resting conditions (lower left) or after stimulation with VEGF 165 , 10 ng/mL (upper left); the effect of VEGF on loop formation, in comparison to medium alone, is clearly evident in the upper panel. 5 (upper panels) and 6 (lower panels) were added at different concentration on VEGF-stimulated cells; both 5 and 6 are able to reduce, in a concentration-dependent manner, the ability of VEGF to induce loops formation. The graphs describe the effect of addition of 5 (purple) and 6 (green) on VEGF-induced neovessel formation measured as total number of loops (left graph) or total branch length (right graph). Data are expressed as mean ± SEM of 5 separate experiments. Asterisks indicate significant differences with respect to the positive control (basal medium + VEGF), with p < 0.05, according to a two-tailed paired t -test. Negative controls (basal medium only) are also shown.

Article Snippet: For this reason, antiangiogenic agents are used to impede or retard cancer progression and metastasis (Ferrara and Adamis, ).

Techniques: Activity Assay, Analogues, Comparison, Concentration Assay, Positive Control, Two Tailed Test

Journal: Scientific Reports

Article Title: Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents

doi: 10.1038/s41598-026-37059-z

Figure Lengend Snippet: Effect of nicorandil (Nic) and aflibercept (Afl) on blood pressure. ( a ) Systolic (SBP), ( b ) diastolic (DBP), and ( c ) mean arterial pressure (MBP). Ctrl: control group, Afl: aflibercept group (10 mg/kg twice a week subcutaneously), Nic: nicorandil group (10 mg/kg/day via drinking water), and Com: combination group (aflibercept [10 mg/kg twice a week] + nicorandil [10 mg/kg/day via drinking water]). n = 6 in each group, *indicates p < 0.05 according to two-way analysis of variance (ANOVA) test.

Article Snippet: The antiangiogenic agent aflibercept (ZALTRAP IV infusion) was purchased from Sanofi K. K. (Tokyo, Japan).

Techniques: Control

Journal: Scientific Reports

Article Title: Potential impact of nicorandil on the pharmacodynamics of anti-angiogenic agents

doi: 10.1038/s41598-026-37059-z

Figure Lengend Snippet: ( a ) Comparison of tumor volume (mm 3 ) between the four treatment groups. Ctrl: control group, Afl: aflibercept group (10 mg/kg twice a week subcutaneously), Nic: nicorandil group (10 mg/kg/day via drinking water), and Com: combination group (aflibercept [10 mg/kg twice a week] + nicorandil [10 mg/kg/day via drinking water]). n = 4–6 in each group, *indicates p < 0.05 according to two-way analysis of variance (ANOVA) test. ( b ) In vivo imaging analysis of tumor bearing mice. Luminescent images derived from MDA-MB-231-Luc cells subcutaneously transplanted in the back of the nude-mice was taken from the IVIS system. Pictures were taken 35 days after drug treatment initiation.

Article Snippet: The antiangiogenic agent aflibercept (ZALTRAP IV infusion) was purchased from Sanofi K. K. (Tokyo, Japan).

Techniques: Comparison, Control, In Vivo Imaging, Derivative Assay